Securities ▲▼ | Shares | Value | |||||
|---|---|---|---|---|---|---|---|
Q4 2023 ▲▼ | Q1 2024 ▲▼ | Change ▲▼ | Q4 2023 ▲▼ | Q1 2024 ▲▼ | Weight (%) ▲▼ | Change ▲▼ | |
| Liquidia Corporation(LQDA) | 10,360,945 | 10,360,945 | 0 | $124.64M | $152.82M | 40.40% | +$28.18M |
| Alimera Sciences Inc | 16,835,154 | 16,835,154 | 0 | $72.73M | $65.66M | 17.36% | -$7.07M |
| Anika Therapeutics Inc | 1,081,360 | 1,435,993 | +354,633 | $24.50M | $36.47M | 9.64% | +$11.97M |
| Evolus, Inc.(EOLS) | 1,317,856 | 1,888,881 | +571,025 | $13.88M | $26.44M | 6.99% | +$12.57M |
| Exelixis, Inc.(EXEL) | 910,730 | 1,100,730 | +190,000 | $21.85M | $26.12M | 6.90% | +$4.27M |
| Verona Pharma PlcADS | 183,064 | 1,296,447 | +1,113,383 | $3.64M | $20.86M | 5.51% | +$17.22M |
| Enanta Pharmaceuticals, Inc.(ENTA) | 0 | 858,070 | +858,070 | $0 | $14.98M | 3.96% | +$14.98M |
| Agios Pharmaceuticals, Inc.(AGIO) | 441,833 | 484,711 | +42,878 | $9.84M | $14.17M | 3.75% | +$4.33M |
| Y-Mabs Therapeutics Inc | 1,048,425 | 587,276 | -461,149 | $7.15M | $9.55M | 2.52% | +$2.40M |
| Outlook Therapeutics, Inc.(OTLK) | 0 | 500,000 | +500,000 | $0 | $5.97M | 1.58% | +$5.97M |
| BioCryst Pharmaceuticals, Inc.(BCRX) | 0 | 758,502 | +758,502 | $0 | $3.85M | 1.02% | +$3.85M |
| NovaBridge BiosciencesADS(NBP) | 0 | 756,538 | +756,538 | $0 | $1.41M | 0.37% | +$1.41M |
| Adma Biologics Inc | 473,087 | 0 | -473,087 | $2.14M | $0 | — | -$2.14M |
| Societal Cdmo Inc | 1,689,768 | 0 | -1,689,768 | $592.3K | $0 | — | -$592.3K |
| Standard BioTools Inc.(LAB) | 7,042,413 | 0 | -7,042,413 | $15.56M | $0 | — | -$15.56M |